Ab­b­Vie dumps an ear­ly-stage drug in $225M Alzheimer's al­liance with Alec­tor

Back in No­vem­ber, as Bio­gen and the con­tro­ver­sy sur­round­ing Aduhelm soaked up the at­ten­tion around Alzheimer’s R&D, Alec­tor qui­et­ly pre­sent­ed Phase I da­ta for an Ab­b­Vie-part­nered pro­gram at the an­nu­al con­fer­ence for Clin­i­cal Tri­als on Alzheimer’s Dis­ease. At the time, Alec­tor said a Phase II tri­al was be­ing planned for the sec­ond half of 2022.

A few weeks ago, though, Alec­tor told in­vestors that it’s “cur­rent­ly re­view­ing po­ten­tial next steps for the AL003 pro­gram to­geth­er with Ab­b­Vie.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER